CareDx has a transplant-testing franchise that taps into recurring surveillance demand and has deeper integration into ...
Zacks Investment Research on MSN
CareDx completes Naveris acquisition and expands oncology reach
CareDx CDNA recently completed the acquisition of Naveris, expanding its presence in high-growth specialty oncology. The ...
CareDx (CDNA) is back in focus after Medicare finalized a Local Coverage Determination for molecular testing in solid organ ...
CareDx stock has delivered a very strong 273.8% return over the past three years. However, its current valuation checks and ...
Zacks Investment Research on MSN
CareDx (CDNA) moves 35.6% higher: Will this strength last?
CareDx CDNA shares rallied 35.6% in the last trading session to close at $40.34. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session.
CareDx (CDNA) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.03 per share a year ago. These figures are ...
Below is Validea's guru fundamental report for CAREDX INC (CDNA). Of the 22 guru strategies we follow, CDNA rates highest using our Small-Cap Growth Investor model based on the published strategy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results